"Thiones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sulfur-containing compounds also known as thioketones of general formula R2C=S.
| Descriptor ID |
D013871
|
| MeSH Number(s) |
D01.928 D02.886.753
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiones".
Below are MeSH descriptors whose meaning is more specific than "Thiones".
This graph shows the total number of publications written about "Thiones" by people in this website by year, and whether "Thiones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 4 | 0 | 4 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 4 | 0 | 4 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiones" by people in Profiles.
-
Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. J Pharm Sci. 2020 06; 109(6):2000-2008.
-
Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
-
Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097.
-
Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorg Med Chem. 2020 01 01; 28(1):115244.
-
Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples. J Pharm Biomed Anal. 2019 Jun 05; 170:124-131.
-
Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. Eur J Med Chem. 2019 May 15; 170:16-27.
-
Cryogenic Fabrication of Dry Powders to Enhance the Solubility of a Promising Anticancer Drug, SHetA2, for Oral Administration. AAPS PharmSciTech. 2019 Jan 02; 20(1):20.
-
Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. Eur J Med Chem. 2018 Oct 05; 158:720-732.
-
Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. J Pharm Sci. 2018 12; 107(12):3179-3186.
-
Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. Eur J Pharm Biopharm. 2018 Sep; 130:272-280.